PRE-TREATMENT TESTS
FOR MCTL THERAPY
What to prepare before travelling for MCTL treatment — antigen panels, HLA typing, imaging, organ function tests, and infection screening. Arrive ready, not delayed.
analyticsAt a Glance
- check_circleAntigen panel and HLA typing are essential pre-requisites
- check_circleCompleting tests before travel saves weeks of delay
- check_circleIncomplete records can lead to admission refusal
- check_circleCancerFax helps identify test gaps before you travel
Required Pre-Treatment Tests: Overview
Most centres require all of these before confirming eligibility. Check with your treating center for any protocol-specific additions.
| Test Category | What It Assesses | Why It Matters for MCTL |
|---|---|---|
| Pathology (histology) | Cancer type, grade, morphology | Confirms diagnosis; identifies cancer cells eligible for MCTL targeting |
| Tumour antigen expression (IHC) | Which TAAs are expressed (MAGE, WT1, NY-ESO-1, survivin, AFP, etc.) | Determines which antigens to include in the T-cell training panel |
| HLA typing | Patient's HLA-A, HLA-B, HLA-C alleles | Determines which peptide targets can be presented by the patient's MHC molecules — essential for antigen matching |
| NGS / molecular profiling | Mutation status, TMB, MSI, driver mutations | Identifies biomarkers affecting immunotherapy rationale; guides combination decisions |
| Recent imaging (CT or PET-CT) | Current disease burden, lesion size and location | Assesses disease extent and confirms patient is medically stable for treatment |
| CBC | Blood counts (lymphocytes, neutrophils, platelets) | Minimum lymphocyte counts required for leukapheresis and cell expansion |
| Organ function (LFT, RFT) | Liver and kidney function | Determines tolerance for conditioning chemotherapy and cell infusion |
| Infection screening | Hepatitis B, Hepatitis C, HIV, CMV, EBV, TB | Active infections may exclude eligibility or require treatment before cell therapy |
| Thyroid and immune markers | TSH, autoimmune panel | Required if toripalimab or another PD-1 inhibitor is included in the protocol |
| ECOG performance status | Functional capacity (0–4 scale) | Most programs require ECOG 0–2; poor performance status often excludes eligibility |
Why HLA Typing Is Critical
HLA typing is frequently overlooked by patients preparing for MCTL — but it is one of the most important pre-requisite tests.
“HLA typing determines which peptide targets can actually be presented by your immune system — without it, antigen selection for T-cell training cannot be personalised.”
What HLA Typing Determines
The HLA (Human Leukocyte Antigen) system defines which peptide fragments a patient's MHC molecules can display to T cells. In MCTL, antigen peptides must be matched to the patient's specific HLA alleles to ensure effective T-cell activation.
Where to Get HLA Typed
HLA typing is available at university hospitals, transplant centers, and specialty immunology labs in most countries. Results can typically be available within 1–2 weeks. CancerFax can help identify local labs if this test is not available through the patient's usual team.
Preparation Steps: How to Organise Your Workup
A structured approach to gathering documents prevents last-minute gaps that delay treatment.
- 1
Audit Your Existing Documents
Collect all current reports: pathology, IHC, NGS, imaging, blood tests, treatment history, discharge summaries. Identify what is missing or outdated.
- 2
Check Antigen Panel Availability
Confirm whether your IHC panel includes MAGE-A, WT1, NY-ESO-1, survivin, AFP, or other relevant tumor-associated antigens. If not, arrange a supplementary panel.
- 3
Arrange HLA Typing
If not already done, arrange HLA-A, HLA-B, HLA-C typing at a local lab. Results typically take 1–2 weeks.
- 4
Get Updated Imaging
Most centers require imaging from within 4–6 weeks of admission. If your latest scan is older, arrange a new CT or PET-CT before travel.
- 5
Submit to CancerFax for Gap Analysis
CancerFax reviews your complete file against the treating center's specific requirements and identifies any remaining gaps before you book travel.
Frequently Asked Questions
Related MCTL Resources
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Not Sure What Tests You Still Need Before MCTL Treatment?
CancerFax reviews your current documents against the requirements of the treating centre and tells you exactly what's missing — before you book flights or pay deposits.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.